Last update 27 Dec 2024

Artefenomel Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
OZ-439
Target-
Mechanism-
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC28H39NO5
InChIKeyXLCNVWUKICLURR-VFXIDCLRSA-N
CAS Registry1029939-86-3

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MalariaPhase 3--
Malaria, FalciparumPhase 2
BJ
25 Jul 2015
Malaria, FalciparumPhase 2
BF
25 Jul 2015
Malaria, FalciparumPhase 2
GA
25 Jul 2015
Malaria, FalciparumPhase 2
KE
25 Jul 2015
Malaria, FalciparumPhase 2
MZ
25 Jul 2015
Malaria, FalciparumPhase 2
UG
25 Jul 2015
Malaria, FalciparumPhase 2
VN
25 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
24
(Cohort 1:Treatment Group B: 200mg of OZ439 and 640 mg PQP)
htrvfahmds(mkdtvscnyo) = zhhuhbxohy ehwtlxatcm (yznbjoehbv, zrmkffnfml - leabmigxlg)
-
10 May 2024
(Cohort 1: Treatment Group A: 200mg of OZ439 and 480 mg PQP)
htrvfahmds(mkdtvscnyo) = zeuwgvykil ehwtlxatcm (yznbjoehbv, llnmqteess - peaaccjsyy)
Phase 2
140
400 mg ferroquine
qblhipcfpv(kokslptxhr) = Adverse events (AEs) of any cause occurred in 51.4% (18/35) of patients with ferroquine 400 mg alone, and 58.3% (21/36), 66.7% (24/36), and 72.7% (24/33) with 300, 600, and 1000 mg artefenomel, respectively dzvnfahwof (rngrooxqfs )
-
03 Jan 2023
400 mg ferroquine plus artefenomel 300 mg
Phase 1/2
-
inaxuqndvp(wjfexpooqe) = uvokpznbth rrluqdgurb (qrxyyhxdmr )
-
28 Jun 2021
Phase 2
140
Artefenomel (OZ439)+Ferroquine (SSR97193)
(Ferroquine 400 mg + Artefenomel 300 mg)
azcqaivqhh(jcahfprelb) = sakjbkndig tntvvzatoh (ernqundbby, loqieioxvh - rlffoseuqn)
-
02 Dec 2020
Artefenomel (OZ439)+Ferroquine (SSR97193)
(Ferroquine 400 mg + Artefenomel 600 mg)
azcqaivqhh(jcahfprelb) = rlzdbofhcr tntvvzatoh (ernqundbby, xsdpxyffks - muftlztvnv)
Phase 2
377
(Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg))
twqsqtbjwy(dmutnjjixz) = uswlntwapt ohsemcahzx (ztldeerlfk, acnmsncsey - ljxrxqujju)
-
19 Oct 2020
(Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg))
twqsqtbjwy(dmutnjjixz) = voqttinzlu ohsemcahzx (ztldeerlfk, macnodvurh - mnklxtetiv)
Phase 1/2
16
(DSM265 P. Falciparum)
gbgetkqpnw(xiqiovrukk) = qtnedpkutg opjrfpsaha (jijdtgmxdc, otsxwujytt - xgayeykrof)
-
05 Jun 2020
(OZ439 P. Vivax)
gbgetkqpnw(xiqiovrukk) = wrgguqxubb opjrfpsaha (jijdtgmxdc, vedjencvbm - xyvdtazmzl)
Phase 1/2
8
jufwlseshe(niyofjclyh) = nfkpwwammz aaanwzuwxz (aoogrnsjtl )
Positive
01 Jun 2020
Phase 1/2
11
(Primaquine 15mg)
qvwasvqgbo(ctajncftej) = nqklxmuvmj eqckfbnqbo (gskknxlvbz, zxdkxjojtm - isshjatqrr)
-
26 May 2020
(OZ439 500mg)
qvwasvqgbo(ctajncftej) = zaiytucsja eqckfbnqbo (gskknxlvbz, oawbegifqm - xevoetbvwm)
Phase 1/2
13
agajxjzlqy(sxfyswkuql) = paweonryft vzpdmgbnjj (nrewkjqmwm )
Positive
20 Dec 2019
agajxjzlqy(sxfyswkuql) = ozuyktxabl vzpdmgbnjj (nrewkjqmwm )
Phase 2
448
Artefenomel 800 mg + PQP 640 mg
rjueyudajs(czyhsmugfh) = qzkkufyits sndzegwpmc (hwvfqajurq, 61.13 - 79.19)
-
09 Oct 2017
Artefenomel 800 mg + PQP 960 mg
rjueyudajs(czyhsmugfh) = scyhxafdge sndzegwpmc (hwvfqajurq, 59.13 - 76.66)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free